Pharma Corruption: the impact of the new UK Bribery Act
This article was originally published in Scrip
Executive Summary
New UK legislation rushed through parliament before the general election on 6 May will have huge consequences as a result of pharma's operations in emerging markets, says Elizabeth Sukkar.